Department of Hepatobiliary Surgery and Institute of Advanced Surgical Technology and Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ann Surg Oncol. 2021 Feb;28(2):797-805. doi: 10.1245/s10434-020-09390-w. Epub 2020 Nov 28.
The impact of tumor necrosis relative to prognosis among patients undergoing curative-intent resection for hepatocellular carcinoma (HCC) remains ill-defined.
Patients who underwent curative-intent resection for HCC without any prior treatment between 2000 and 2017 were identified from an international multi-institutional database. Tumor necrosis was graded as absent, moderate (< 50% area), or extensive (≥ 50% area) on histological examination. The relationship between tumor necrosis, clinicopathologic characteristics, and long-term survival were analyzed.
Among 919 patients who underwent curative-intent resection for HCC, the median tumor size was 5.0 cm (IQR, 3.0-8.5). Tumor necrosis was present in 367 (39.9%) patients (no necrosis: n = 552, 60.1% vs < 50% necrosis: n = 256, 27.9% vs ≥ 50% necrosis: n = 111, 12.1%). Extent of tumor necrosis was also associated with more advanced tumor characteristics. HCC necrosis was associated with OS (median OS: no necrosis, 84.0 months vs < 50% necrosis, 73.6 months vs ≥ 50% necrosis: 59.3 months; p < 0.001) and RFS (median RFS: no necrosis, 49.6 months vs < 50% necrosis, 38.3 months vs ≥ 50% necrosis: 26.5 months; p < 0.05). Patients with T1 tumors with extensive ≥ 50% necrosis had an OS comparable to patients with T2 tumors (median OS, 62.9 vs 61.8 months; p = 0.645). In addition, patients with T2 disease with necrosis had long-term outcomes comparable to patients with T3 disease (median OS, 61.8 vs 62.4 months; p = 0.713).
Tumor necrosis was associated with worse OS and RFS, as well as T-category upstaging of patients. A modified AJCC T classification that incorporates tumor necrosis should be considered in prognostic stratification of HCC patients.
在接受根治性切除术治疗肝细胞癌(HCC)的患者中,肿瘤坏死与预后的关系仍未明确。
从一个国际多机构数据库中确定了 2000 年至 2017 年间未接受任何先前治疗而行根治性切除术治疗 HCC 的患者。组织学检查时,肿瘤坏死程度分为无(无坏死)、中度(<50%面积)或广泛(≥50%面积)。分析了肿瘤坏死与临床病理特征和长期生存之间的关系。
在 919 例行根治性切除术治疗 HCC 的患者中,肿瘤中位大小为 5.0cm(IQR,3.0-8.5)。367 例(39.9%)患者存在肿瘤坏死(无坏死:n=552,60.1%;<50%坏死:n=256,27.9%;≥50%坏死:n=111,12.1%)。肿瘤坏死程度也与更晚期的肿瘤特征相关。HCC 坏死与 OS(中位 OS:无坏死,84.0 个月;<50%坏死,73.6 个月;≥50%坏死,59.3 个月;p<0.001)和 RFS(中位 RFS:无坏死,49.6 个月;<50%坏死,38.3 个月;≥50%坏死,26.5 个月;p<0.05)相关。广泛(≥50%)坏死的 T1 肿瘤患者的 OS 与 T2 肿瘤患者相当(中位 OS,62.9 与 61.8 个月;p=0.645)。此外,T2 疾病伴坏死患者的长期结局与 T3 疾病患者相当(中位 OS,61.8 与 62.4 个月;p=0.713)。
肿瘤坏死与 OS 和 RFS 更差相关,并导致患者 T 分期升级。在 HCC 患者的预后分层中,应考虑纳入肿瘤坏死的改良 AJCC T 分类。